4MichaelHD JonathanH MarioDG etal.Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat .美国医学会杂志：中文版,1999,18(4):177-183.
5Grundy SM, Benjamin CI, Burke GL, et al. Diabetes and cardiovascular disease [ J ]. Circulation, 1999,100:1134-1146.
6Jing F,Michael HA. The NHANES I epidemiologic follow -up study 1971-1992[J]. JAMA, 2000,283:2404-2410.
7Assmann G, Schulte H, Cullen P. New and classical risk factors -the Munster heart study (PROCAM)[J]. Eur J Med Res, 1997,16:237-242.
8Matsuura P, Yamashita S, Nakamura T,et al. Effect of visceral fat accumulation on uric acid metabolism in male obese subjects:visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity [J ]. Metabolism,1998,47:929-933.
9Hosoya T. Obesity and hyperuricaemia [J ]. Journal of the Japanese Society for the Study of Obesity. 1998,14: 79-85.
10Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomlzed, double - blind trial[J]. Circulation, 2003, 20, 107(19) :2409- 15.
